AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03752970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
Trial: NCT00354575
Drug: Chinese Herb: CCH1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
Trial: NCT04385550
Drug: AK105 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
Trial: NCT04343222
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An NSAID used to treat eye pain and swelling
Trial: NCT03225846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride
Trial: NCT01747551
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01883102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
Trial: NCT01868425
Drug: multimodal:acetaminophen, gabapentin, ketamine, bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
Trial: NCT01868425
Drug: placebo pills and injectables
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
Trial: NCT00397670
Drug: Drug: BufferGel® with diaphragm
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03796377
Drug: St Johns Wort Extract
RxNorm normalized name: St Johns wort extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
Trial: NCT02839889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for two weeks, followed by two week open-label period
Trial: NCT04353505
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
Trial: NCT00542542
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50-250 mcg IV over 1-4 hours during surgery.
Trial: NCT01730014
Drug: 148-0287-A-4.2mM-cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
Trial: NCT01730014
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
Trial: NCT01730014
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
Trial: NCT01156077
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TR-701 FA 200 mg will be given as a single oral dose
Trial: NCT01156077
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
Trial: NCT02548286
Drug: CKD-330 8/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, 1day or 22day
Trial: NCT02801695
Drug: Citrulline
RxNorm normalized name: Citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citrulline supplementation
Trial: NCT02801695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00783276
Drug: SYN115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg single dose
Trial: NCT00783276
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO
Trial: NCT00547014
Drug: Placebo Comparator: Cohort 1 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: placebo for cohort 1 as single dose
Trial: NCT00547014
Drug: Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
Trial: NCT00547014
Drug: 52364 100 mg
RxNorm normalized name: TUBE FEEDING GT 20FR ROSS#51364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 52364 100 mg capsule administered as a single dose
Trial: NCT00211068
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
Trial: NCT01718808
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
Trial: NCT00450515
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04557267
Drug: Higher-dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage 3
Trial: NCT04557267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01805453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
Trial: NCT04223804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT02993406
Drug: Matching placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take matching placebo tablet orally once daily
Trial: NCT01824927
Drug: Steroids eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use steroids eye drops to decrease the pain.
Trial: NCT01237236
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02963051
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals
Trial: NCT00663962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
Trial: NCT02922985
Drug: Intravenous acetominophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose if 1 gram intravenous to be given pre-surgery
Trial: NCT02922985
Drug: Ketorolac, intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of 60 mg Intramuscular to be given at time of skin closure
Trial: NCT02922985
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
Trial: NCT00063817
Drug: Conditioning Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Trial: NCT03241264
Drug: ND-L02-s0201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified day
Trial: NCT01053637
Drug: hydrocodone/acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
Trial: NCT00003050
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003050
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01147211
Drug: MK2206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
Trial: NCT02385240
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02311673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT04315350
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone is given together with curcumin-placebo
Trial: NCT02988050
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil used for conscious sedation.
Trial: NCT02988050
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: With local anaesthetic for skin infiltration.
Trial: NCT02349425
Drug: Placebo (for gefapixant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally
Trial: NCT00616902
Drug: Placebo Injection 4 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
Trial: NCT04703205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
Trial: NCT02325713
Drug: Cysticide
RxNorm normalized name: Crystacide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
Trial: NCT02325713
Drug: Cysticide
RxNorm normalized name: Crystacide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
Trial: NCT03301155
Drug: Anaferon for children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT03301155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT00448201
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 5 mg/m\^2 per day on days +1, +3 and +6
Trial: NCT03918239
Drug: SHP643
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive injection of SHP643.
Trial: NCT02548975
Drug: Statin, beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving either statin or beta blockers prior to cardiac surgery.
Trial: NCT00196989
Drug: GW677954
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01492179
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline would be administered intravenously and intra-abdominally.
Trial: NCT04505839
Drug: STP1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, QD
Trial: NCT04640831
Drug: 5 Methoxy N,N Dimethyltryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH001 administered via inhalation
Trial: NCT02564380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01519089
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Trial: NCT01519089
Drug: CP-690, 550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Trial: NCT00201708
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Trial: NCT00201708
Drug: Cyclophosphamide (AC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Trial: NCT00685698
Drug: TG-873870 (Nemonoxacin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg
Trial: NCT04239469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00040651
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03215862
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
Trial: NCT01219907
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01500226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (4 X 0 mg capsules) 0 mg PO
Trial: NCT01915147
Drug: OXN PR followed by OxyPR tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05082753
Drug: Stromectol ® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Ivermectin tablets were administered orally.
Trial: NCT01986270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03788759
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo, as an adjunct to antipsychotic medication.
Trial: NCT02604836
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated oral ibandronate tablet (150 mg) once-monthly
Trial: NCT01430234
Drug: Panzytrat 25.000 FIP-E units of Lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
Trial: NCT04296266
Drug: Alda-341
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement d-limonene orally administered as a drug.
Trial: NCT02653612
Drug: EC17 imaging contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Trial: NCT02678520
Drug: Casodex, Zoladex , Lupron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.
Trial: NCT01146600
Drug: Clarithromycin followed by placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
Trial: NCT01146600
Drug: Placebo then Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
Trial: NCT00078000
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929330
Drug: GI198745 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
Trial: NCT00978367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Trial: NCT00978367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Trial: NCT00978367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
Trial: NCT03435692
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and occurring more than 30 minutes after the block if applicable.
Trial: NCT03435692
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
Trial: NCT01668433
Drug: Regimens (Primaquine, Methylene blue)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
Trial: NCT03134378
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT02182050
Drug: BIBF 1120 ES high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182050
Drug: Placebo to BIBF 1120 ES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01208103
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02726399
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
Trial: NCT00162916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornstarch
Trial: NCT00980109
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
Trial: NCT01641159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
Trial: NCT00980109
Drug: placebo for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.